[Lipid-lowering effect of bezafibrate in patients with diabetes mellitus and hyperlipidaemia (author's transl)].

No abstract is available for this paper.

• Publication year

  1978

• Venue

  Deutsche Medizinische Wochenschrift

• Publication date

  1978-08-04

• Fields of study

  Medicine

• Identifiers
  DOI 10.1055/S-0028-1129237PMID 668570
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The effect of clofibrate on glucose tolerance, insulin secretion, triglycerides and fibrinogen in patients with coronary heart disease.

  2009cited by this paper
• Comparison of clofibrate with halofenate in diabetics with hyperlipidaemia.

  1977cited by this paper
• Effect of BM 15.075 on lipoprotein concentrations in different types of hyperlipoproteinaemia.

  1977cited by this paper
• Letter: Potentiation of hypoglycemic effect of sulfonylureas by clofibrate.

  1976cited by this paper
• Potentiation of hypoglycemic effect of sulfonylureas by halofenate.

  1975cited by this paper
• Effect of clofibrate on plasma glucose and serum immunoreactive insulin in patients with hyperlipoproteinemia.

  1974cited by this paper
• Binding of certain acidic drugs to human albumin: Theoretical and practical estimation of fundamental parameters

  1974cited by this paper
• [Diabetes and hyperlipoproteinaemias (author's transl)].

  1974cited by this paper
• [Clinical picture and treatment of insulin resistance in primary hyperlipoproteinaemia (author's transl)].

  1973cited by this paper
• [Incidence of hyperlipoproteinaemia in patients with chemical and clinical diabetes (author's transl)].

  1973cited by this paper
• Mortality experience of diabetic patients. A twenty-six-year follow-up study.

  1971cited by this paper
• Serum lipids in an ambulary diabetic clientele. Effect of therapy with Atromidin (clofibrate).

  1970cited by this paper
• HYPERLIPIDEMIA IN AN ADULT DIABETIC POPULATION.

  1970cited by this paper
• Long‐term monitoring during clofibrate therapy

  1970cited by this paper
• Effect of CPIB ester on plasma free fatty acid levels in man.

  1966cited by this paper
• Vascular disease and serum lipids in diabetes mellitus. Observations over thirty years (1931-1961).

  1963cited by this paper
• Circulating lipids in diabetes mellitus.

  1959cited by this paper
• A test for symmetry in contingency tables.

  1948cited by this paper

• Bezafibrate ameliorates diabetes via reduced steatosis and improved hepatic insulin sensitivity in diabetic TallyHo mice

  2017influential citation
• Bezafibrate Improves Insulin Sensitivity and Metabolic Flexibility in STZ-Induced Diabetic Mice

  2016cites this paper
• Bezafibrate improves insulin sensitivity and metabolic flexibility in STZ-treated diabetic mice

  2016cites this paper
• Effects of bezafibrate on lipid and glucose metabolism in dyslipidemic patients with diabetes: the J-BENEFIT study

  2012cites this paper
• Ligand‐ and Structure‐Based Drug Design Strategies and PPARδ/α Selectivity

  2012cites this paper
• [Improvement in diabetes control by treatment with bezafibrate].

  2008cites this paper
• Wirkung von Bezafibrat bei primären Hyperlipidämien

  2005cites this paper
• Cost-Effectiveness Study of a Lipid-Lowering Therapy in Hyperlipoproteinaemia Type IIb and Type IV (Frederickson)

  1993cites this paper
• Effects of slow release bezafibrate on the lipid pattern and on blood glucose of type 2 diabetic patients with hyperlipidaemia.

  1992cites this paper
• Effects of Gemfibrozil and Other Fibric Acid Derivatives on Blood Lipids and Lipoproteins

  1991cites this paper
• Effects of bezafibrate on insulin secretion and peripheral insulin sensitivity in hyperlipidemic patients with and without diabetes.

  1989cites this paper
• Steady-state kinetics of bezafibrate retard in hyperlipidemic geriatric patients

  1988cites this paper
• Bezafibrate and fenofibrate in type II diabetics with hyperlipoproteinaemia.

  1987cites this paper
• Fettstoffwechsel bei Typ II Diabetes mellitus

  1986cites this paper
• [The somatostatin infusion test for the evaluation of glucose utilization in bezafibrate medication].

  1984cites this paper
• [Bezafibrate in primary hyperlipidemias (author's transl)].

  1982cites this paper
• [Carbohydrate metabolism in bezafibrate therapy. Controlled study of glibenclamide-treated diabetics with hyperlipidemia].

  1982cites this paper
• [Effect of bezafibrate on the carbohydrate metabolism of 17 diabetics with hyperlipidemia].

  1981cites this paper
• [Comparative double-blind investigation of bezafibrate and clofibrate in patients with primary hyperlipoproteinaemia].

  1980cites this paper
• Pharmacokinetics of bezafibrate after single and multiple doses in the presence of renal failure

  1980cites this paper
• Chapter 19 Disorders of Lipid Metabolism

  1979cites this paper
• Disposition pharmacokinetics of bezafibrate in man

  1979cites this paper
• [Progress in the area of drug development. 12].

  1977cites this paper